Difference between revisions of "Team:UofC Calgary/Judging"
| Line 307: | Line 307: | ||
<p class="c-font-white">Our project was continually informed by discussions with professionals in the field. See our human practices efforts on our <a href="https://2016.igem.org/Team:UofC_Calgary/Human_Practices">Human Practices</a> pages. </p> | <p class="c-font-white">Our project was continually informed by discussions with professionals in the field. See our human practices efforts on our <a href="https://2016.igem.org/Team:UofC_Calgary/Human_Practices">Human Practices</a> pages. </p> | ||
</ul> | </ul> | ||
| − | |||
| − | |||
| − | |||
</div> | </div> | ||
</div> | </div> | ||
Revision as of 05:30, 16 October 2016
Bronze Requirements
- Register and Attend
- Wiki
- Poster
- Presentation
- Sample Submission
- Safety Forms
- Judging Form
- Attributions
- Parts Page
- New Part BBa_K2008003
The University of Calgary registered for and attended the 2016 iGEM Jamboree in Boston!
Our team created the great Wiki you're currently using!
The U of Calgary 2016 team created the beautiful and informative poster that was exhibited at the 2016 iGEM Jamboree!
We will be presenting our accomplishments over the summer to the judges at the Giant Jamboree in Boston!
Our samples were submitted to iGEM headquarters on __________. You can find the details of the submissions here.
All of our safety forms were submitted on time throughout the summer. See them on our Safety page
Judging forms have been submitted on October 14th, 2016. You can find them here
You can find the contributions of each of our members as well as our numerous amazing mentors on our Attributions page
See all the parts we have designed on our Parts page
We designed and characterized a gene construct coding for the radioprotective peptide mBBI attached to a secretion tag, TD1 tag for secretion and transdermal delivery, as well as GFP for easy transformation recognition. Find it on our parts page here
Silver Requirements
- Part Characterization BBa_K2008005
- Collaboration
- Human Practices
This part contains an active nonamer from the Bowman Birk Protease Inhibitor (BBI) with the addition of lysine, serine, cysteine, and isoleucine (KSCI) tag on the N-terminal end and a phenylalanine (F) tag on the C-terminal end to increase BBI solubility. A B. subtilis secretory signal peptide sequence is included to allow for secretion of the peptide directly into surrounding media. A transdermal tag (TD1, BBa_K1074000) is fused to the N-terminus of BBI to allow for diffusion of the peptide across the skin. This coding sequence is under the control of the constitutive B. subtilis promoter pVeg (BBa_K143012) and a strong B. subtilis RBS (BBa_K780001).
We characterized this part by testing the effect of the BBI peptide in cell culturing experiments using both wildtype fibroblasts (1BR3) as well as colon cancer cells (HCT116). We further characterized the delivery capabilities of our TD1 tag by administering patch prototypes to mice, and then performing mass spectrometry on the mice blood a few days after patch administration to detect the presence of our peptide in the mice blood.
We have collaborated with various iGEM teams as well as certain local organizations for the improvement of our project and for the promotion of iGEM. See all of our collaborations on our Collaborations page.
Our project was continually informed by discussions with professionals in the field. See our human practices efforts on our Human Practices pages.
Gold Requirements
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed elit diam nonummy nibh euismod tincidunt ut laoreet dolore magna aluam erat volutpat. Ut wisi enim ad minim veniam quis nostrud exerci et tation diam nisl ut aliquip ex ea commodo consequat euismod tincunt ut laoreet dolore magna aluam
- Integrated Human Practices
- Improving upon a previous part
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed elit diam nonummy nibh euismod tincidunt ut laoreet dolore.
